Short interfering RNA (siRNA), a small duplex of RNA fragment, has proved as an extremely useful research tool to interrogate gene functions in test tubes. However, the transformation of siRNAs from a functional genomic tool into a new therapeutic modality has been hindered by ineffective delivery methods for systemic administration. In this review, we will discuss the recent advances in formulating new delivery strategies that target siRNAs to specific cells following systemic administration. Special emphasis will be given to leukocytes, since siRNA delivery remains exceptionally challenging here due to the unavailability of effective delivery technologies. We will not only detail new platforms that utilize leukocyte integrins as receptor targets for siRNAs delivery, but also show how one of these strategies has been utilized for in vivo drug target validation of a novel anti-inflammatory target, cyclin D1, for inflammatory bowel diseases.
Introduction
RNA interference (RNAi) is a sequence-specific endogenous gene-silencing mechanism conserved in many organisms. [1] [2] [3] In 1998, Fire et al. discovered that long double-stranded RNA (dsRNA) mediates RNAi in worms. 4 Subsequently in 2001, Elbashir et al. demonstrated that endogenous RNAi machinery could be activated by the introduction of synthetic small-interfering RNAs (siRNAs) to the cytoplasm of mammalian cells, inducing potent silencing of specific genes of interest. 5 These key scientific accomplishments in RNAi have led to a fundamentally new approach for treating various illnesses by addressing targets that had otherwise been 'undruggable' using existing therapeutic approaches. Undruggable molecules include those that lack ligand-binding domains or those that share too high a degree of structural homologies with their targets. Such undruggable molecules can be made accessible by a sequence-specific inactivation of the target gene expression by RNAi-based approaches.
Recent examples include potential targets for the treatment of hyperlipidemia such as PCSK9 and ApoB-100. Although these have long been considered "undruggable" using conventional small-molecule approaches, RNAi-based methods have successfully suppressed ApoB-100 and PCSK9 expression in the liver, and reduced serum cholesterol levels. 6, 7 In addition, unlike most other drug classes today that act at the protein level, the ability of RNAi to block drug targets at the mRNA level provides a significant mechanistic advantage.
RNAi pathways can be activated on purpose either by expressing short hairpin RNA (shRNA) with viral vectors, or by directly incorporating synthetic siRNAs into the cell cytoplasm. 8, 9 The use of synthetic siRNAs as drugs for gene silencing eliminates the clinical safety concerns associated with viral vectors. In addition, siRNAs, which enter the late stage of the endogenous RNAi pathway, are less likely to interfere with the physiologic gene regulation carried out by the endogenous microRNA machinery. In fact, siRNAs now represent the most promising type of RNAi-based therapeutics currently advancing in preclinical and clinical trials. 8, 10 Several clinical trials involving siRNAs are being conducted in the treatments of age-related macular degeneration (AMD), ischemia reperfusion injury in the kidney, respiratory syncytial virus (RSV) infection, and cancers (Table 1) .
Despite the promise as a new form of medicine, the biggest hurdle facing the translation of siRNAs into clinical applications is delivery. 8, 11 The efficiency with which synthetic siRNAs cross the plasma membrane and enter the cytoplasm is usually very low unless suitable carriers are used. In addition, unmodified naked siRNAs are subject to rapid renal clearance and are degraded by RNases, shortening their half-life in vivo. Another concern is that siRNAs could stimulate the immune system by being recognized by Toll-like receptors, thereby provoking interferon responses, causing cytokine induction, and activating coagulation cascades. These can cause global suppression of gene expression as well as aberrant immune activation, generating off-target effects and misinterpreted therapeutic outcomes. 12 One recent example of such a case involves the VEGF-siRNAs currently used in clinical trials for AMD. The VEGF-siRNAs was found to induce the desired biological effect (i.e., suppression of angiogenesis) not by internalizing to the cytoplasm in which to mediate direct silencing of the VEGF pathway. Instead, the siRNA bound to cell-surface Toll-like receptor 3 (TLR3), and activated TLR3 in a sequence-and target-independent manner, suppressing angiogenesis via off-target effects. 13 This has raised serious concerns as to the specificity and safety of siRNAs in clinical trials, and thereby emphasized the importance of appropriate delivery Systemic and targeted siRNA delivery systems that ensure the incorporation of siRNAs to the cytoplasm of target cells.
In this review, we present the recent progress made in systemic siRNA delivery technologies. We will then examine a newly emerging delivery platform: integrin-targeted and stabilized nanoparticles (I-tsNP) that are optimized to leukocyte-implicated diseases. Finally, we will discuss one specific application for in vivo drug target validation that involved the use of I-tsNP to identify cyclin D1 as a potential new target for inflammation.
siRNA Delivery Technologies
Local delivery. Diseases limited to mucosal or subcutaneous tissues can be treated via the local delivery of naked or cationic lipid/ polymer-formulated siRNAs, as has been shown in various animal models (e.g., the upper respiratory tract, 14 vagina, 15 eyes 16 and in subcutaneous tumors 17 ). Many of ongoing clinical trials employ local siRNA delivery, such as intraocular injection of VEGF-siRNA for the treatment of AMD, or intranasal injection of RSV-siRNA for the treatment of RSV infection (Table 1) . Although the local siRNA delivery mitigates risks and toxicity associated with systemic injection of siRNAs and delivery vehicles, many high profile diseases are not fully accessible by local delivery and do require systemic delivery approaches.
Systemic siRNA delivery. Systemic delivery of siRNAs remains the most challenging task at hand. In order to achieve efficient therapeutic gene silencing, the siRNA must find its cellular target after first overcoming multiple obstacles including hostile environments, where it can be easily degraded, anatomical barriers (such as the liver), and areas of poor cellular uptake, any or all of which can thwart efficient gene silencing. Demonstrating effective gene silencing in humans via a systemic siRNA application would mark the next milestone for the realization of RNAi-based therapeutics in a clinical setting.
The first systemic RNAi therapeutics regimen, which seeks to treat ischemia reperfusion injury in the kidney during cardiac surgery by targeting the pro-apoptotic gene p53, has recently entered clinical trials. 9 The second systemic RNAi therapeutics, and the first to target cancers (in this case, solid tumors), has also recently entered a phase I/II clinical trial (Table 1) . Additional siRNA based medicines are expected to enter clinical evaluation in the coming year. Yet, not a single siRNA treatment has yet won clinical approval.
Nevertheless, unique and sophisticated delivery strategies are rapidly emerging, allowing for the possibility of cell type-specific targeting of siRNAs in a safe and efficient manner. The challenges involved in devising such systems include: (1) targeting siRNAs to the appropriate cell-type to improve pharmacokinetics and minimize collateral damage; (2) devising the internalization across the plasma membrane and escape from the endosome, ensuring efficient release of siRNAs in the cell cytoplasm; (3) evading the immune system to avoid the induction of aberrant immune stimulation; and (4) designing a fully degradable system that mitigates safety concerns.
Fortunately, in developing such a system one can take advantage of the uniform physicochemical properties inherent to synthetic siRNAs. 18 It is therefore likely that such a platform will permit the delivery of different siRNAs with negligible modifications, unlike other drug delivery systems, which require individual optimizations due to the highly variable physicochemical properties of each drug molecule. 19 To date, several nano-carriers ( Fig. 1 ) have been devised that induce gene silencing via systemic siRNA delivery in animal models. We will discuss most of these in the following sections.
Passive siRNA delivery. Nano-dimension liposomes and related particles have represented the major approach for systemic siRNA delivery. By exploiting the inherited tendency of these particles to passively accumulate to the liver, the major efforts have been focused on delivering siRNAs for the treatment of liver diseases such as hyperlipidemia, liver cancer and virus hepatitis.
Stable nucleic acid-lipid particles (SNALP)
. SNALP are nontargeted cationic liposomes 7, 20 (Fig. 1A) . SNALP has a well-defined stable lipid bilayer structure (~100 nm) that encapsulates siRNAs within it, as opposed to a lipoplex structure composed of a mixture of siRNAs and cationic lipids. The SNALP consists of a lipid bilayer containing a mixture of cationic and fusogenic lipids that enables the cellular uptake and endosomal release of a particle's nucleic acid payload. A diffusible polyethylene glycol-lipid (PEG-lipid) conjugate coating provides SNALP a neutral, hydrophilic exterior and which stabilizes a particle during formulation. This surface coating also shields the cationic bi-layer in vivo, preventing rapid systemic clear- Cationic lipidoid-containing liposomes (Fig. 1B ) have been generated to deliver ApoB-and Factor VII-siRNAs in order to induce silencing in the liver, resulting in a more than 80% reduction in mRNA levels in mice. The lipidoid-based liposomes were also tested in non-human primates with a single i.v. injection of either 2.5 or 6.25 mg/Kg siRNAs against ApoB. The result was a rapid serum ApoB decrease of more than 50% within 3 days. This decrease was maintained for up to 2 weeks following intravenous injection. Increases in both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) indicated the possibility of liver toxicity. No response by the immune system to the lipoids (e.g., cytokine induction) was noted.
Atelocollagen. Atelocollagen is a biomaterial consisting of a lowimmunogenic fraction of pepsin-digested type I collagen of calf dermis. 23, 24 Positively charged lysine and hydroxylysine residues rich in collagens are thought to help an atelocollagen-siRNA complex formation and a subsequent incorporation of the complex into cells. Atelocollagen has been used to deliver RPN2-siRNA to beast cancer cells in vivo, overcoming the chemo-resistance of cancer cells to docetaxel.
Active (targeted) siRNA delivery. Specific antibodies, ligands and peptide ligand mimetics have been used to direct nano-carriers to target cells and tissues. The active targeting aims not only to accumuance. One bio-distribution study in mice indicated that ~28% of siRNAs were distributed in the liver and ~8% in the spleen, whereas only 0.3% were found in the lung. Slight distribution to the lung is thought to be one characteristic that distinguishes SNALP from lipoplex aggregates made of conventional cationic lipids. In the liver, not only hepatocytes but also Kupffer cells took up siRNAs delivered by SNALP. Such an occurrence is likely to negatively affect their delivery to hepatocytes. In one non-human primate study monkeys given i.v. 1 or 2.5 mg/kg ApoB-siRNA formulated in SNALP exhibited a 68% and 90% reduction, respectively, in ApoB mRNA 48 h after injection. The 2.5 mg/kg dose resulted in a ~90% mRNA reduction in the liver for up to 11 days. Only one minor adverse was observed: liver enzyme release. Despite the presence of cationic lipids in the SNALP formulation, which could trigger adverse effects, mice and non-human primates studies did not reveal any major toxicities in the liver. A clinical trial is planned to deliver siRNAs with SNALP for the treatment of liver cancer.
Lipidoid. A new class of synthetic lipid-like molecules, termed lipidoids, has recently been generated. By employing parallel synthesis, these lipid-like molecules allow one to carry out the rapid synthesis of a large library containing over 1,200 structurally diverse lipidoids. 21, 22 Several cationic lipidoids have been identified that greatly facilitate the specific silencing while formulated with siRNAs. Systemic and targeted siRNA delivery
Cyclodextrin-containing polycation (CDP).
CDP is a polymer with a cyclic oligomeric glucose backbone that self-assembles into a colloidal particle (~50 to 70 nm) upon complexation with siRNAs 34, 35 (Fig. 1G) . CDP seems less toxic than conventional cationic polymers such as PEI. CDP particles are surface decorated with transferrin (Tf )-coupled PEG for targeting purposes. Although Tf receptors (TfR) are expressed in many tissues, they are upregulated in cancers. In a mouse model bearing subcutaneous tumors, 3 consecutive daily doses of Tf-targeted CDP nanoparticles carrying 2.5 mg/kg of two different siRNA sequences targeting ribonucleotide reductase subunit M2 (RRM2) slowed tumor growth.
In a subsequent non-human primates safety experiment, 36 The RRM2-siRNA (3, 9 or 27 mg/kg) formulated in Tf-PEG-decorated CDP were i.v. administered to non-human primates. Whereas 3 and 9 mg/kg doses were well tolerated, a dose of 27 mg/kg induced an elevation in blood urea (potentially indicative of kidney toxicity) and a mild increase in liver enzyme levels, as well as a mild increase in IL-6 levels. Multiple injections over 18 days induced antibodies to human Tf. A new treatment involving Tf-coupled CDP containing RRM2-siRNAs recently entered phase II clinical trials for the treatment of ovarian cancer (Table 1) .
Integrin-Targeted and Stabilized Nanoparticles (I-tsNP) as a Vehicle for siRNA Delivery to Leukocyte-Implicated Diseases
Despite the progress made in engineering systemic siRNA delivery to the liver and solid tumors, such delivery to leukocytes remains challenging and less advanced. Systemic siRNA delivery to leukocytes holds great promise not only for streamlining drug discovery (by facilitating in vivo drug target validation), but also for facilitating the development of an RNAi-based therapy platform for leukocyteimplicated diseases such as inflammation; blood cancers (lymphoma, leukemia, myeloma), and leukocyte-tropic viral infections (HIV, ebola, dengue). 37 However, leukocytes continue to be among the most difficult targets for siRNA delivery 38 due to the fact that they are resistant to conventional transfection reagents, and that they disperse in the body, making it difficult to successfully localize or passively deliver siRNAs via systemic administration. 39 To circumvent these problems, we have utilized a leukocyte cell-specific integrin approach and developed integrin-targeted stabilized nanoparticles (I-tsNPs). 40 Integrins as receptor targets for siRNA delivery. Integrins are the largest family of cell adhesion molecules that mediate cell-cell and cell-matrix interactions across a wide range of physiological and pathophysiological contexts. 41, 42 Integrins are α/β heterodimeric cell surface proteins; to date, 15 α-subunits and 8 β-subunits have been identified in vertebrates, forming at least 24 distinct α/β heterodimers. Among the 24 integrin family members, β 2 and β 7 integrins are exclusively expressed on leukocytes. Integrins on leukocytes mediate the adhesive interactions critical for cell migration to sites of inflammation.
Antibodies to integrins on leukocytes have been used to inhibit inflammatory reactions in vivo as well as in patients. Two humanized antibodies, Efalizumab (Raptiva TM ) and Natalizumab (Tysabri TM ), have been FDA-approved for the treatment of autoimmune diseases. 43, 44 In this way, antibodies "targeting" leukocyte integrins have been used to interfere with the adhesive interactions of leukocytes for the treatment of inflammatory disorders. To extend the utility of leukocyte integrin-targeting across a broad range of late in close proximity to the target, improving the pharmacokinetics and mitigating collateral damage, but also to actively cross the cell membrane, escorting siRNAs into the cytoplasm in which to activate RNAi pathways.
Cholesterol-siRNA conjugate. The covalent attachment of cholesterol moiety to siRNAs have been shown to improve the pharmacokinetics of siRNAs (Fig. 1C) . 25, 26 The tissue specificity of siRNA delivery is determined by the types of lipoprotein particles, such as LDL and HDL, to which cholesterol-siRNA conjugates are incorporated in circulation. Whereas LDL-bound cholesterol-siRNAs are largely taken up by the liver, HDL-bound cholesterol-siRNAs are taken up by adrenal glands, the ovary, kidney and liver. Intravenous (i.v.) injection of cholesterol-conjugated chemically modified (2'-O-methyl sugar modification) apoB-siRNA (50 mg/kg) to mice led to the reduction of apoB mRNA in both the liver and jejunum.
Another conjugate class is comprised of dynamic polyconjugates. 27, 28 Major features of this conjugate type include the presence of a membrane-active polymer, the ability to reversibly mask the activity of the polymer until it reaches the acidic environment of endosomes, and the capacity to target hepatocytes (Fig. 1D) . To facilitate active siRNA delivery to hepatocytes, the dynamic polyconjugates employ N-acetylgalactosamine binding to the asialoglycoprotein receptor on hepatocytes. In one study, a dynamic polyconjugate (~10 nm in size) containing ApoB-siRNA (2.5 mg/kg) was i.v. injected into mice. After 48 h, an 80% reduction in ApoB mRNA in the liver was observed.
Targeted cationic liposomes. Hepatic stellate cells reside in the sinusoid of the liver in which to play a critical pathogenic role for the liver fibrosis. To selectively target hepatic stellate cells that efficiently uptake vitamin A via receptors for retinol binding protein, vitamin A was coupled to cationic liposomes. 29 Vitamin A-coupled liposomes complexed with siRNA to the key fibrogenesis factor HSP47 homolog were injected to cirrhotic mice, silencing the gene in the liver and resolving fibrosis.
Another example of targeted cationic liposomes is liposomepolycation-DNA (LPD) nanoparticles formed by encapsulating in unilamellar cationic liposomes the protamine-condensed mixture of siRNAs and a carrier calf thymus DNA (Fig. 1E) . The LPD nanoparticles were then surface modified with PEG-linked anisamide, a small-molecule compound binding to sigma receptors, which are overexpressed in certain cancers. 30, 31 In tumor-bearing mice, EGFR-siRNA delivered with the targeted anisamide-PEG-LPD nanoparticles resulted in a increase in sensitivity to chemotherapy (cisplatin). Injection of siRNA formulated within the nanoparticles induced a significant increase in serum cytokine levels (IL-6, IL-12, IFN), an effect which could cause significant adverse effects.
Targeted PEI nanoplex. RGD (Arg-Gly-Asp) peptide binds to α V integrins highly expressed in certain cancers and in tumor vasculature. RGD peptide coupled via PEG to a cationic polymer polyethylenimine (PEI) 32, 33 (Fig. 1F ). Upon complexation with siRNAs, this RGD-PEG-PEI forms a polyplex aggregate with the RGD-PEG component exposed on its surface. The RGD-PEG-PEI nanoplex disperses into separate particles (~100 nm in diameter), each with a positive surface charge. I.V. administration of 2 mg/ kg VEGFR-siRNAs formulated in the nanoplex every three days significantly suppressed the growth of subcutaneously transplanted tumors in nude mice. I-tsNP made from natural biomaterials. I-tsNPs are made from neutral unilamellar nano-scale (~120 nm in diameter) liposomes surface modified with the glycosaminoglycan hyaluronan 40 (Fig.  2) . As the cationic lipids and polymers that form lipoplexes and polyplexes are non-natural and cause multiple toxic effects (including cytokine induction and liver damage), the use of a neutral lipid to form liposomes, one that will not elevate cytokine or liver enzyme levels, offers a safe strategy. I-tsNPs are small unilamellar liposomes that possess a defined size, and can be easily downsized by extrusion to provide a reproducible nano-scaled system.
Hyaluronan as a stabilizing agent. Coating small unilamellar liposomes with the glycosaminoglycan hyaluronan endows carriers with key advantages. Hyaluronan is a built-in cryo-protectant that stabilizes particles during a cycle of lyophilization and rehydration. 50 Hyaluronan also serves as a scaffold to which antibodies can attach themselves, thereby endowing nanoparticles with a targeting capacity. siRNAs were encapsulated within I-tsNPs when the lyophilized particles underwent rehydration with water containing protamine-condensed siRNAs, resulting in ~80% encapsulation efficacy and a payload of ~4,000 siRNA molecules per particle. 40 The siRNAs entrapped within the I-tsNP were protected from degradation and demonstrated effective silencing even after pre-incubation with RNAse A or 50% serum for two hours prior to cell transfection. Furthermore, I-tsNPs encapsulating siRNAs do not induce interferon responses or lymphocyte activation in vitro.
I-tsNP entrapping siRNAs induce potent gene silencing. A single i.v. injection of 2.5 mg/kg Ku70-siRNAs, induced ~80% reduction of a reference target Ku70 expression in β 7 integrin-positive mononuclear leukocytes. Silencing of Ku70 was not observed in mononuclear leukocytes from β 7 -integrin knockout mice identically treated, demonstrating a robust in vivo gene silencing with the high specificity of targeting.
Validation of Cyclin D1 as an anti-inflammation target using I-tsNP. In vivo drug target validation represents an exceptionally important and challenging step for drug development, demanding the understanding of functions of target molecules in the complex setting of disease in vivo. 51 Loss-of-function studies have typically been performed using the germline knockout approach. However, despite recent technological innovations, 52 generation of knockout mice remains demanding and time-consuming. This approach is further limited by issues of embryonic lethality and compensaleukocyte-implicated diseases (such as inflammation, allergy, blood cancers and viral infection), we have recently developed an siRNA delivery strategy by targeting leukocytes via those integrins expressed on hematological cells.
The use of β 2 and β 7 integrins for leukocyte-directed siRNA delivery is supported by a number of lines of evidence, detailed hereafter.
Exclusive expression. A subset of integrins (i.e., β 2 and β 7 integrins) is exclusively expressed on leukocytes, thereby enabling the selective targeting of hematologic cells.
Efficient receptor internalization. Integrins are constitutively internalized and recycled in leukocytes. Integrin recycling facilitates the internalization of bound antibodies and peptides, 45 ,46 a prerequisite for activating RNAi pathways with siRNAs.
Activation-dependent conformational changes. One of the unique features of integrins is that their ability to bind ligands is dynamically upregulated via conformational changes. 41 In resting cells, integrins predominantly exist in a low-affinity conformation and, only upon activation, are they transiently converted to a high-affinity conformation. Aberrant affinity modulation of integrins has been demonstrated in a variety of leukocyte-implicated diseases. 47, 48 Targeting the high-affinity form of integrins is expected to enable selective siRNA delivery for aberrantly activated leukocytes. By leaving naïve cells untouched, selective targeting would be advantageous in reducing iatrogenic immune defects.
By employing an LFA-1 single chain antibody (scFV)-protamine fusion protein (Fig. 1H) that not only complexes siRNAs via a positively charged protamine moiety, but that also directs the siRNAs-fusion protein complex to the target, we have demonstrated a proof of principle that integrins can be used for siRNA delivery to leukocytes. 39 A similar approach that employed anti-CD7 scFv linked to a positively charged 9-arginine peptide have shown an effective delivery of CCR5-and viral Vif/Tat-siRNAs to human T cells in vivo in humanized mice, effectively blocking HIV infection. 49 A potential drawback of the antibody-protamine fusion protein approach is, however, its low payload (5 siRNA molecules per delivery carrier), which could undermine its clinical usefulness. Thus, to increase payload and achieve robust targeted gene silencing in leukocytes in vivo, we have created integrin-targeted stabilized nanoparticles (I-tsNP) 40 (Fig. 2) . effective and specific gene silencing in target cells, while mitigating off-target effects. Further technological advancement and innovation in the next few years should help establish siRNA delivery platform technologies applicable for patients.
tory changes of gene expression. Gene silencing with siRNAs has emerged as a simple strategy to achieve rapid and effective suppression of protein expression. In this way RNAi holds the potential to dramatically accelerate in vivo drug target validation and therapy development if it can be effectively applied to target cells in vivo. 51 Here we show an example of siRNA-based in vivo drug target validation using I-tsNP. Cyclin D1 (CyD1), part of the cyclin protein family, whose function is to serve as the regulatory subunits of cyclin/cyclin-dependent kinase (Cdk) holoenzymes responsible for regulating both entry into, and progression throughout, the cell cycle. [53] [54] [55] CyD1/CDK4 and CyD1/CDK6 complexes phosphorylate retinoblastoma protein, leading to the progression from the G 1 to S phase. Amplification or overexpression of CyD1 has been implicated in the aberrant proliferation and pathogenesis of several cancers. CyD1 is considered as a therapeutic target for cancers.
CyD1 is expressed in a broad range of leukocyte subsets including T-lymphocytes and upregulated upon stimulations. Leukocyteexpressed CyD1 is upregulated at sites of inflammation such as inflamed gut in inflammatory bowel diseases (IBD); 56, 57 however, its roles in the pathogenesis of inflammation remain elusive. We have shown that CyD1 play an important role in the induction of pro-inflammatory cytokines in activated lymphocytes, potentially serving as a novel anti-inflammatory therapeutic target. 40 In activated lymphocytes, CyD1 upregulation is required for the induction of pro-inflammatory cytokines TNFα and IL-12 p40. This effect is independent of the CyD1-driven cell cycle progression, because the same effect was observed even when cell cycle was arrested with a DNA polymerase inhibitor aphidicolin. The induction of TNFα and IL-12 p40 depends on upregulation of CyD1 but not other D-type cyclins cyclin D2 or cyclin D3. Furthermore, while CyD1 knockdown with siRNA resulted in downregulation of TNFα and IL-12 p40 expression, IL-10 remained upregulated.
To validate CyD1 as a novel anti-inflammatory target for IBD, I-tsNP-entrapped CyD1-siRNAs (2.5 mg/kg) was intravenously injected into mice with DSS-induced colitis. 40 I-tsNP-delivered CyD1-siRNAs potently reduced CyD1 mRNAs, as well as TNFα and IL-12 mRNA levels, comparable to that of the uninflamed gut. Remarkably, CyD1 knockdown led to a drastic reduction of intestinal inflammation and tissue destruction. CyD1-knockdown did not induce pathologic cell death of lymphocytes in the gut and periphery, possibly because CyD1 is dispensable for normal proliferation, but not aberrant expression of TNF and IL12. CyD2 and CyD3 are likely to support physiologic lymphocyte proliferation in the absence of CyD1.
Summary
RNAi now opens up new avenues to explore mechanism-oriented molecular medicine, in which the critical component of the disease pathogenesis is specifically and deliberately blocked in patients. 58 The realization of RNAi-based mechanism-oriented medicine is, however, facing the major challenge, systemic and targeted siRNA delivery. To overcome this, one has to consider strategies not only to increase the exposure of target cells to siRNAs, but also to effectively cross the plasma membrane and reach appropriate intracellular compartments in which to exploit endogenous RNAi pathways. The development of robust siRNA delivery technologies is imperative that must enable 
